Is Ovarian Cancer Under-Served by Personalized Medicine?

Ovarian cancer is the most fatal gynecological cancer, and among the most fatal of all cancer types. The five year survival rate for ovarian cancer is 44.6%, which (remarkably) is exactly half that of breast cancer. This means that while there are over 10 times as...

U.S. Behind the Curve in RAS Mutation Testing

In news from last month’s European Society for Medical Oncology Congress in Madrid, it appears that the United States lags behind the European Union in comprehensiveness of testing for RAS mutations. Experts now agree that expanded RAS testing is needed for...

Prognostic Applications Are Growing Rapidly for Cancer Biomarkers

The number of publications that describe novel biomarkers for cancer has grown by an average of 24% over the last 5 years. As previously reported, this growth rate is essentially the same as for novel biomarkers across all diseases. This isn’t surprising since...

10 Biomarkers to Watch in Oncology

We decided to mine the biomarkers being used in clinical trials for interesting test development opportunities, and we began with Oncology as the first therapeutic area to explore. Our basic methodology was to identify biomarkers that are in regular (and hopefully...

Genetic Testing Is Becoming More Routine At Cancer Hospitals

This article provides a nice summary of progress in using biomarkers to help treat cancer. One of the key takeaways is how much potential there is to understand the precise differences in tumors, and how different drugs will affect each of them. The article references...